Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief education intervention, for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache.

Conditions

Chronic Migrane, Medication Overuse Headache, Migrane

Brief summary

Change from baseline in the number ofMHDs (Weeks 1-4)

Detailed description

Change from baseline in MMDs (Weeks 1-12), Change from baseline in MHDs (Weeks 1-12), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 4), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 12), Change from baseline in average Daily Pain assessment score (Weeks 1-2), Change from baseline in monthly days with acute medication use (Weeks 1-4), Change from baseline in monthly days with acute medication use (Weeks 1-12, Change from baseline in the number ofMHDs (Weeks 1-4)

Jensen RH, Lundqvist C, Schytz HW, Tassorelli C, Vernieri F, Lanteri-Minet M, Terwindt GM, Blumenfeld A, Tepper SJ, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB.

2026-03-26

10.1212/wnl.0000000000214863

Interventions

DRUGVYEPTI 100 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in the number ofMHDs (Weeks 1-4)	—

Secondary

Measure	Time frame
Change from baseline in MMDs (Weeks 1-12), Change from baseline in MHDs (Weeks 1-12), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 4), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 12), Change from baseline in average Daily Pain assessment score (Weeks 1-2), Change from baseline in monthly days with acute medication use (Weeks 1-4), Change from baseline in monthly days with acute medication use (Weeks 1-12, Change from baseline in the number ofMHDs (Weeks 1-4)	—

Measure

Time frame

Change from baseline in MMDs (Weeks 1-12), Change from baseline in MHDs (Weeks 1-12), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 4), Not fulfilling the ICHD-3 diagnostic criteria for CM nor MOH (Week 12), Change from baseline in average Daily Pain assessment score (Weeks 1-2), Change from baseline in monthly days with acute medication use (Weeks 1-4), Change from baseline in monthly days with acute medication use (Weeks 1-12, Change from baseline in the number ofMHDs (Weeks 1-4)

—

Countries

Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden

Outcome results

None listed